CareDx (CDNA) stock surged 5.90% in pre-market trading on Wednesday, fueled by an analyst rating upgrade from Wells Fargo.
The healthcare company's shares received a significant boost after Wells Fargo upgraded its rating on CDNA from "Underweight" to "Equal-Weight", signaling improved sentiment towards the stock. Despite lowering their price target from $28 to $24 per share, the new target still represents potential upside from current trading levels.
CareDx enjoys an average "overweight" rating from analysts covering the stock, according to data from FactSet. The mean price target among analysts stands at $32.25, further highlighting the positive outlook and growth prospects for the company.